A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Latest Information Update: 01 Apr 2025
At a glance
- Drugs NEU 411 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Neuron23
Most Recent Events
- 24 Mar 2025 Results published in the Neuron23 Media Release.
- 24 Mar 2025 According to a Neuron23 media release, the company plans to present Initial findings from this trial at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™), taking place April 1-5 in Vienna. The Company plans to present full results from the study, including modulation of phosphorylated Rab10 and di-22:6-bis(monoacylglycerol)-phosphate (BMP), at a future conference.
- 12 Jun 2024 Status changed from recruiting to completed.